This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug |
Toxicity |
Interaction Type |
Mechanism |
Reference |
|---|
| Doxycycline (564-25-0) | Ergotism | Synergistic | Unknown | Systemic arterial spasms Ergotamine tartrate
|
| Enoxaparin (9005-49-6) | Ergotism | Synergistic | heparin results in a 25% increase in the
AUC of subcutaneously administered dihydroergotamine | Ergotism as complication of thromboembolic prophylaxis with heparin and dihydroergotamine
|
| Enoxaparin (9005-49-6) | Peripheral Ischaemia | Synergistic | heparin results in a 25% increase in the
AUC of subcutaneously administered dihydroergotamine | Ergotism as complication of thromboembolic prophylaxis with heparin and dihydroergotamine
|
| Erythromycin (114-07-8) | Ischaemic Chest Pain | Synergistic | Erythromycin is potent inhibitors of the cytochrome P450 isoenzyme CYP3A4, an enzyme involved in the metabolism of ergot derivatives | Severe vascular spasm due to erythromycin-ergotamine interaction
|
| Paroxetine (61869-08-7) | Diaphoresis | Synergistic | Not understood,Dihydroergotamine is a 5-HT agonist while paroxetine and sertraline are both serotonin (5-HT) reuptake inhibitors, all of which might be expected to increase 5-HT concentrations in the CNS, and thereby increase receptor stimulation | Serotonin syndrome complicating migraine pharmacotherapy
|
| Paroxetine (61869-08-7) | Diffuse Weakness | Synergistic | Not understood,Dihydroergotamine is a 5-HT agonist while paroxetine and sertraline are both serotonin (5-HT) reuptake inhibitors, all of which might be expected to increase 5-HT concentrations in the CNS, and thereby increase receptor stimulation | Serotonin syndrome complicating migraine pharmacotherapy
|
| Paroxetine (61869-08-7) | Dilated Pupils | Synergistic | Not understood,Dihydroergotamine is a 5-HT agonist while paroxetine and sertraline are both serotonin (5-HT) reuptake inhibitors, all of which might be expected to increase 5-HT concentrations in the CNS, and thereby increase receptor stimulation | Serotonin syndrome complicating migraine pharmacotherapy
|
| Paroxetine (61869-08-7) | Dysarthria | Synergistic | Not understood,Dihydroergotamine is a 5-HT agonist while paroxetine and sertraline are both serotonin (5-HT) reuptake inhibitors, all of which might be expected to increase 5-HT concentrations in the CNS, and thereby increase receptor stimulation | Serotonin syndrome complicating migraine pharmacotherapy
|
| Sumatriptan (103628-46-2) | Coronary Vasoconstriction | Additives | the drugs may have additive vasoconstrictive effects | The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
|